FirstWord: Market Research Reports

... boost some GHD brands in the US? Opportunity lurks in the US Growth hormone Deficiency treatment landscape. Although 3 established brands dominate, promoters ... Issues NPS+ GHD (US) explores key issues affecting brand loyalty for growth hormone manufacturers. You’ll learn: How satisfied the growth hormone market ...

... European oncologists to find out how satisfied they are with non-small cell lung cancer (NSCLC) drugs. Which brand outscored its nearest rival by almost ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by answering ...

... 100 US oncologists to find out how satisfied they are with non-small cell lung cancer (NSCLC) drugs. Which brand outscored its nearest rival by almost ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by answering ...

... in clinical trials, the report reveals candid insights about the psoriasis landscape from 12 key opinion leaders (KOLs) in North America and Europe. You ... treatments for psoriasis. Find out what they are and how KOLs expect them to influence use. Personalised care is on the horizon: KOLs believe ...

... strategy and build a more compelling case for specialty drugs with FirstWord’s new report, The Cost of Specialty Drugs: Payer Perspectives. Click here to view the ... in approaches to managing specialty drug costs and the challenges faced by payers today. Read it to understand how the market is responding to rapidly rising specialty drug costs – and assess ...

... medical affairs: oral therapies outperforming in Europe. How does your team measure up? In Europe’s Multiple Sclerosis (MS) market, medical affairs teams for oral ... ’s team ranks highest, and where your team stands in Medical Affairs Reputations: MS. The report compares teams for 10 major MS treatments ...

... medical affairs: oral therapies outperforming in the US. How does your team measure up? In the US multiple sclerosis (MS) market, medical affairs teams for oral therapies ... ’s team ranks highest, and where your team stands in Medical Affairs Reputations: MS. The report compares teams for 10 major MS treatments ...

... Loyalty Issues NPS+ Melanoma (US) explores key issues affecting brand loyalty for melanoma drug manufacturers. You’ll learn: How satisfied the melanoma market is. How ... Based on Expert Knowledge We surveyed 150 Medical Oncologists from the EU5 (France, Italy, Germany, Spain, UK), chosen from the largest ...

... more than one option. Why? FirstView’s NPS+ Melanoma report assesses brand loyalty for 7 melanoma treatments. See exactly how your brand is performing ... Loyalty Issues NPS+ Melanoma (US) explores key issues affecting brand loyalty for melanoma drug manufacturers. You’ll learn: How satisfied the melanoma market is. How ...

... create services to deliver these results for your business? Find out in Success in Value Added Services. Click here to view the sample pages Through expert insights, Success in Value Added Services unravels step-by-step details on how to build Value Added Services into your value proposition ...

... for any given patient.” - US KOL Expert insight into the COPD treatment landscape KOL Insight: Wet Age-Related Macular Degeneration covers 3 marketed drugs and 9 ... excited by its use of a new pathway, are KOLs optimistic about RG7716’s prospects for treating AMD? DE-120 (Santen): What obstacles does DE- ...

What’s on the KOL ‘wish list’ for the next generation of IPF treatments? Physicians currently only have two options for Idiopathic Pulmonary Fibrosis (IPF) sufferers: how ... of Medicine in the Department of Allergy, Pulmonary, and Critical Care Medicine at the Vanderbilt University Medical Centre in Nashville. KOLs from Europe Prof. Alessandro ...

... through implementing Value Added Services. How can you create services to deliver these results for your business? Through expert insights, Success in Value Added Services unravels step-by-step details on how to build Value Added Services into your value ...

... physician’s good customer experience is your biggest asset! Positive customer engagement with healthcare professionals (HCP) builds loyalty to your brands ... initiatives fail to engage physicians and HCPs? Wider support: How can stakeholders work with pharma to create a mutually beneficial customer experience? Evaluation: What ...

Satisfaction survey: One brand dominates EU5 Asthma/COPD market. Can your brand compete? Which asthma/COPD brand scored twice as high as its closest competitor ... Loyalty Issues NPS+ asthma/COPD (EU5) explores key issues affecting brand loyalty for drug manufacturers. You’ll learn: How satisfied the asthma/COPD market is. How ...

... to Key Questions about Asthma/COPD Treatments Advair (fluticasone propionate/salmeterol; GSK): Advair and Symbicort have similar NPS scores. Which brand has ... Loyalty Issues NPS+ asthma/COPD (US) explores key issues affecting brand loyalty for drug manufacturers. You’ll learn How satisfied the asthma/COPD market is. How ...

... to build an effective health economic and outcomes research team Health Economic and Outcomes Research (HEOR) teams play a critical market access role from refining clinical research and building a brand ... , Global Outcomes & Epidemiology within a top 50 global pharmaceutical manufacturer A Health Economics Director, Europe, within a top 50 global pharmaceutical manufacturer A Vice President, Health Economics and Outcomes Research ...

... US. Endocrinologists in both markets most often prescribe the same three leading brands. Market Access Impact: GHD explores key issues affecting Growth Hormone manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...

... . Endocrinologists in both markets most often prescribe the same three leading brands. Market Access Impact: GHD explores key issues affecting Growth Hormone manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...

... in Medical Affairs Reputations: HIV. You’ll learn how infectious disease specialists rate the teams for 8 major HIV treatments, whether ... medical affairs services most important to doctors. European doctors more likely to prefer frequent interactions: 50% of EU5 doctors prefer to interact with medical affairs ...

... the top 2 medical affairs teams in the US. How is your team doing? In the past 6 months, the medical affairs teams for two leading HIV treatments reached ... your team compares in Medical Affairs Reputations: HIV. You’ll learn how infectious disease specialists rate the teams for 8 major HIV treatments, whether they’re satisfied ...

... a part, so which model is best and what are the considerations which underpin that choice? This report analyses current orphan drug commercial models, assesses their ... for orphan drugs commercial teams to ensure that their business model works for all stakeholders? Key components: What are the key components of current commercial models ...

... ’s Jakafi (ruxolitinib) is seen as a model application of a PRO strategy – what benefits did the company accrue ... Patients Direct. Linda Deal, Patient-Centered Outcomes Assessment (PCOA) Lead, Global Health & Value, Pfizer. Matt Reaney, Head of Patient-Reported Outcomes, Global Health Economics and Outcomes ...

... or a tool? The huge disconnect between 'health grade' (personal fitness based wearables) and 'med tech' grade wearables continues, but what solutions exist ... ? Which chronic diseases will see wearables having the greatest impact? Critical information on the implementation of wearable tech Analysis of 15+ out-of-industry partnerships ...

Why is the patient voice critical to orphan drug success? Patient input is critical to an orphan drug’s success, but how and when should you engage and what trends and ... report illustrates the exceptional value patient insights bring to the orphan drug development process. “It's really important to engage with patients because they know more about ...

... overcome? To really understand the issues and trends that are shaping the CDx market, ... European Diagnostic Company Companion Diagnostic Expert, Global Diagnostic Company Companion Diagnostic Expert, Specialist ... been withheld. About FirstWord FirstWord is an innovative industry intelligence leader serving over ...

... events that have the potential to impact the treatment landscape of Type 2 Diabetes Mellitus (T2DM). Topics covered include expert opinions on the positive data ...

... events happening in Malignant melanoma (MM): expanded indication label for Bristol-Myers Squibb’s Opdivo plus Yervoy regimen for metastatic melanoma patients regardless of BRAF ... successful do KOLs think Philogen’s Darleukin and Fibromun immunocytokines will be in melanoma? What safety concerns do KOLs have with Darleukin/Fibromun and ...

... Roche’s PD-L1 inhibitor atezolizumab for the treatment of locally advanced or metastatic NSCLC expressing PD-L1, the EMA’s CHMP recommendation for approval of BMS’s Opdivo ... & Co.’s Keytruda (pembrolizumab)? How do KOLs rate PD-L1 as a biomarker to guide the treatment of NSCLC with Roche’s atezolizumab? How do KOLs interpret the recent broadening ...

... your brand compares to your competitors. FirstView’s NPS+ Psoriasis report compares brand loyalty for 8 major psoriasis treatments—information you can use to improve ... Loyalty Issues NPS+ Psoriasis (EU5) explores key issues affecting brand loyalty for Psoriasis drug manufacturers. You’ll learn: How satisfied the psoriasis market is. How ...

... your brand compares to your competitors. FirstView’s NPS+ Psoriasis report compares brand loyalty for 6 major psoriasis treatments—information you can use to improve ... Loyalty Issues NPS+ Psoriasis (US) explores key issues affecting brand loyalty for psoriasis drug manufacturers. You’ll learn: How satisfied the psoriasis market is. How ...

... with nab-paclitaxel for patients with metastatic triple- negative breast cancer (mTNBC); the US Food and Drug Administration (FDA) awarding ... of this expanded indication have on prescriptions of Ibrance and on those of Afinitor? Update Bulletins include expert insight and analysis based on FirstWord analyst re- ...

... , what can Pharma do to ensure positive payer support for its pricing proposals? Pay-for-Performance and Drug Pricing Pressure: Impact and Response from Pharma intensively examines the ... setting the pay-for-performance vs pricing status quo agenda Understand how public payers are reforming health delivery and assess the likely impact on pharma ...

... industry must overcome and are tech giants friends or foes? Designs on the future of Healthcare: the ambitions of Google, Apple et al provides a detailed ... MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business ...

... antibody undergoing Phase IIb evaluation in relapsing remitting multiple sclerosis. Key Questions Answered in this Update Bulletin: How do KOLs feel about the continuation of lower ... GeNeuro’s GNbAC1 antibody undergoing Phase IIb evaluation in relapsing remitting multiple sclerosis? Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement ...

Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF): Topics covered include opinions about Gilead’s suspension of a Phase II trial of ... ? Is simtuzumab’s mechanism of action worthy of further investigation for the treatment of IPF? How do KOLs rate the importance of Boehringer Ingelheim’s Phase IV trial ...

Top medical affairs team safely ahead, but competition for 2nd and 3rd place is fierce In the US non-small cell lung cancer (NSCLC) treatment market, competition among medical affairs teams is fierce. The top team may ...

Four medical affairs teams battling it out for top spot. How does your team compare? In the fiercely competitive European non-small cell lung cancer (NSCLC) treatment market, one medical affairs team leads. But for how long ...

... , KOL Insight: Dyslipidaemia. Request sample pages now. Covering 9 recently marketed drugs, and 6 currently in clinical trials, the report reveals candid insights about the dyslipidaemia landscape from 12 key opinion leaders (KOLs) in North America and Europe. You ...

... identified by 90 marketing professionals working in leading pharma companies across the US and Europe, turn to this insightful chart-based survey report. Answering key ... with speed and confidence. FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and ...

... this update, payers offer their views on the recent reform of the cancer drugs fund (CDF) and its impact on access to cancer immunotherapies in the UK. In light ... ? Will the CDF reform allow improved access to cancer immunotherapies for the treatment of rarer cancers? How will the CDF reform impact the ...

... a profitable voice in the market? Effective Pharma KAM Teams: Challenges and Solutions from the front line shines a spotlight on the challenges facing KAM in 2016 and presents practical ... will get the best out of your KAM team Identify when and where KAM will be most effective and avoid wasting time and money ...

... friends when it comes to drug pricing. Public, health professional, political and payer hostility is growing worldwide as the prices of new drugs for chronic disease, specialty ... of justifying high drug prices to fund innovation and development need an overhaul? Risk Sharing: Are risk-sharing, value-based pricing and pricing by indication the best ...

... on the latest events that have the potential to shape the oncology biosimilars market. Topics covered include opinions about data from Sandoz ... drive down prices to unsustainable levels and cause the biosimilars market in the US to fail? Update Bulletins include expert insight and analysis based on FirstWord ...

... latest events with the potential to shape the targeted treatment of Chronic Lymphocytic Leukaemia (CLL). Topics covered include opinions about the use of ... allow the agent to realise its potential as a successful CLL therapy? Update Bulletins include expert insight and analysis based on FirstWord analyst re- ...

... key opinion leader (KOL) views on recent developments in the chronic obstructive pulmonary disease (COPD) market. Topics covered include the clinical role of MABAs (muscarinic ... with an ICS and an additional anti-inflammatory agent? Will asthma COPD overlap syndrome (ACOS) be recognized by physicians or regulators as a distinct clinical entity ...

... on the latest events that have the potential to shape the hepatitis C virus (HCV) treatment landscape. Topics covered include KOL ... if a short treatment regimen is attractive to KOLs. Key Questions Answered in this Update Bulletin: How do KOLs expect Merck & Co.’s Zepatier (elbasvir and grazoprevir) to be ...

... ACOs friends or foes of pharma and how should the industry expand and adapt its stakeholder engagement strategies for best advantage? Essential ACO Engagement: Mapping New Networks of Influence is essential reading for commercial planners and practitioners ...

... to accept biosimilars of proven targeted treatments. So what do pharma companies need to do to increase confidence and ensure uptake of biosimilars in this toughest of markets? Biosimilars in Oncology: KOL Insight spells out the concerns about equivalence, evidence and endpoints with insights into the current ...

... your research, pricing and life cycle management decision making? Harnessing the Power of Real-World Data is essential reading for market access, sales ... ? Sources of real world data: What are the sources of real world data and what are the challenges in collecting them? Patient power: Patient ... the sources of real world data and the challenges of analysing and interpreting them. Engage with payers and patients to harness the critical ...